HA Fragment‑Driven mTORC1 Activation Couples Extracellular Matrix Degradation to Autophagy Shutdown in Aging
HA Fragment‑Driven mTORC1 Activation Couples Extracellular Matrix Degradation to Autophagy Shutdown in Aging
Background
Aged tissues show declining high‑molecular‑weight (HMW) hyaluronic acid (HA) due to reduced HAS2 expression, which drives fibroblast senescence via a p27‑CDK2‑SKP2 axis [2]. Simultaneously, accumulating low‑molecular‑weight (LMW) HA fragments provoke inflammation through CD44‑PKCα signaling that suppresses the anti‑inflammatory A2a receptor [3]. Autophagy, however, is not simply passive; it actively degrades HAS2 via an ATG9A‑dependent route under starvation or mTOR inhibition [1], positioning autophagy as a brake on HA synthesis. The missing link is how LMW HA fragments might directly inhibit autophagy, tipping the balance toward matrix loss and cellular senescence.
Hypothesis
LMW HA fragments engage CD44 on aged fibroblasts and chondrocytes, triggering a PKCα‑dependent cascade that activates PI3K‑Akt‑mTORC1 signaling and blocks TFEB nuclear translocation, thereby suppressing autophagy flux. This suppression occurs concurrently with HAS2‑driven senescence, creating a dual hit: insufficient HA synthesis for matrix integrity and autophagy inhibition that prevents clearance of damaged organelles and protein aggregates.
Mechanistic Model
- Fragment Sensing – LMW HA binds CD44, inducing its clustering and recruitment of PKCα [3].
- PKCα → PI3K‑Akt – Activated PKCα phosphorylates and activates PI3K, leading to PIP3 production and Akt activation (Ser473).
- Akt → mTORC1 – Akt phosphorylates TSC2, relieving its inhibition of Rheb, thus activating mTORC1.
- mTORC1 → TFEB – mTORC1 phosphorylates TFEB on serine residues, retaining it in the cytoplasm and preventing lysosomal biogenesis and autophagy gene transcription.
- Feedback Loop – Cytoplasmic TFEB fails to upregulate lysosomal genes, reducing autophagosome‑lysosome fusion and further diminishing HAS2 turnover, which sustains low HA synthesis and senescence.
This model extends the existing data by providing a direct causal route from extracellular HA fragments to the core nutrient‑sensing machinery that governs autophagy, rather than relying on parallel inflammatory pathways alone.
Testable Predictions
- Prediction 1: In aged human dermal fibroblasts, exogenous LMW HA (≤200 kDa) will decrease LC3‑II/I ratio and increase p62 accumulation, effects reversible by CD44 blocking antibody or PKCα inhibitor (e.g., Gö6976).
- Prediction 2: LMW HA treatment will increase phospho‑Akt (Ser473) and phospho‑S6K (Thr389) levels, indicating mTORC1 activation; rapamycin treatment will restore TFEB nuclear localization and autophagy flux despite HA fragment presence.
- Prediction 3: Genetic knockdown of TFEB in young fibroblasts will phenocopy the senescence‑associated secretory profile (SASP) seen in aged cells, even when HAS2 is overexpressed.
- Prediction 4: In vivo, intra‑articular injection of LMW HA into mouse joints will elevate joint tissue p‑S6K and reduce LC3‑II autophagy markers, which can be rescued by systemic rapamycin or CD44 deficiency.
Potential Experimental Approach
- Cell Culture: Treat passage‑matched human fibroblasts with HMW vs. LMW HA; measure autophagy flux (mCherry‑GFP‑LC3), mTORC1 activity (p‑S6K), and TFEB localization (immunofluorescence). Include CD44 siRNA, PKCα inhibitor, and rapamycin as interventions.
- Western Blot/qPCR: Assess HAS2, p27, SASP cytokines (IL‑6, IL‑8) after interventions.
- Animal Model: Use aged CD44‑fl/fl;Col1a2‑Cre mice to delete CD44 specifically in fibroblasts; administer LMW HA intra‑dermally and evaluate skin histology, autophagy markers, and senescence (SA‑β‑gal).
- Rescue Experiments: Overexpress a constitutively nuclear TFEB mutant (TFEB‑3SA) in aged fibroblasts to test whether restoring lysosomal biogenesis alleviates senescence despite persistent LMW HA.
If these predictions hold, the hypothesis would redefine autophagy decline in aging as an actively maintained state driven by extracellular matrix breakdown, offering a therapeutic nexus: targeting CD44‑PKCα‑mTORC1 signaling to re‑engage autophagy and mitigate age‑related tissue dysfunction.